Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study

Timothy F. Cloughesy*, Patrick Y. Wen, H. Ian Robins, Susan M. Chang, Morris D. Groves, Karen L. Fink, Larry Junck, David Schiff, Lauren Abrey, Mark R. Gilbert, Frank Lieberman, John Kuhn, Lisa M. DeAngelis, Minesh Mehta, Jeff J. Raizer, W. K Alfred Yung, Ken Aldape, John Wright, Kathleen R. Lamborn, Michael D. Prados

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

147 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science